PL2976074T3 - Antagoniści receptora kannabinoidowego CB1 do zastosowania w leczeniu chorób związanych z neuronowymi nieprawidłowościami dendrytów - Google Patents
Antagoniści receptora kannabinoidowego CB1 do zastosowania w leczeniu chorób związanych z neuronowymi nieprawidłowościami dendrytówInfo
- Publication number
- PL2976074T3 PL2976074T3 PL13710850T PL13710850T PL2976074T3 PL 2976074 T3 PL2976074 T3 PL 2976074T3 PL 13710850 T PL13710850 T PL 13710850T PL 13710850 T PL13710850 T PL 13710850T PL 2976074 T3 PL2976074 T3 PL 2976074T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- receptor antagonists
- diseases associated
- cannabinoid receptor
- neuronal abnormalities
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13710850.2A EP2976074B1 (en) | 2013-03-19 | 2013-03-19 | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities |
| PCT/EP2013/055728 WO2014146699A1 (en) | 2013-03-19 | 2013-03-19 | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2976074T3 true PL2976074T3 (pl) | 2020-07-27 |
Family
ID=47901995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13710850T PL2976074T3 (pl) | 2013-03-19 | 2013-03-19 | Antagoniści receptora kannabinoidowego CB1 do zastosowania w leczeniu chorób związanych z neuronowymi nieprawidłowościami dendrytów |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9662320B2 (pl) |
| EP (1) | EP2976074B1 (pl) |
| CY (1) | CY1122879T1 (pl) |
| DK (1) | DK2976074T3 (pl) |
| ES (1) | ES2781756T3 (pl) |
| HR (1) | HRP20200324T1 (pl) |
| HU (1) | HUE048755T2 (pl) |
| LT (1) | LT2976074T (pl) |
| PL (1) | PL2976074T3 (pl) |
| PT (1) | PT2976074T (pl) |
| RS (1) | RS60295B1 (pl) |
| SI (1) | SI2976074T1 (pl) |
| SM (1) | SMT202000164T1 (pl) |
| WO (1) | WO2014146699A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| IL271464B2 (en) * | 2017-06-30 | 2024-08-01 | Chase Therapeutics Corp | NK-1 antagonist compositions and methods for use in the treatment of depression |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| EP3669876A1 (en) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| EP4525836A4 (en) * | 2022-05-18 | 2026-02-25 | Hadasit Medical Res Services&Development Ltd | COMBINATION OF ENDOCANNABINOIDS AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS |
| EP4568702A1 (en) | 2022-08-12 | 2025-06-18 | Jazz Pharmaceuticals Research UK Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US20060172019A1 (en) | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| EP1737445A4 (en) * | 2004-03-19 | 2007-05-09 | Axonyx Inc | METHOD FOR TREATING DOWN SYNDROME |
| US8222293B2 (en) * | 2004-05-24 | 2012-07-17 | Regents of the University of Carolina | Treating learning deficits with inhibitors of Hmg CoA reductase |
| WO2006012403A1 (en) * | 2004-07-20 | 2006-02-02 | Massachusetts Institute Of Technology | Methods of treatment: cell signaling and glutamate release |
| US20060276549A1 (en) * | 2005-05-13 | 2006-12-07 | Jacobson Peer B | Combination and use of drugs |
| PT1983984T (pt) * | 2006-02-02 | 2018-06-14 | Novartis Ag | Tratamento da esclerosa tuberosa |
| US20080004313A1 (en) * | 2006-06-28 | 2008-01-03 | Mai De Ltd. | Preparation of crystalline polymorphs of rimonabant hydrochloride |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| WO2010020585A1 (en) * | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
| US20130058915A1 (en) * | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
-
2013
- 2013-03-19 PT PT137108502T patent/PT2976074T/pt unknown
- 2013-03-19 SI SI201331699T patent/SI2976074T1/sl unknown
- 2013-03-19 PL PL13710850T patent/PL2976074T3/pl unknown
- 2013-03-19 HU HUE13710850A patent/HUE048755T2/hu unknown
- 2013-03-19 DK DK13710850.2T patent/DK2976074T3/da active
- 2013-03-19 ES ES13710850T patent/ES2781756T3/es active Active
- 2013-03-19 LT LTEP13710850.2T patent/LT2976074T/lt unknown
- 2013-03-19 US US14/778,266 patent/US9662320B2/en active Active
- 2013-03-19 SM SM20200164T patent/SMT202000164T1/it unknown
- 2013-03-19 EP EP13710850.2A patent/EP2976074B1/en active Active
- 2013-03-19 WO PCT/EP2013/055728 patent/WO2014146699A1/en not_active Ceased
- 2013-03-19 RS RS20200303A patent/RS60295B1/sr unknown
- 2013-03-19 HR HRP20200324TT patent/HRP20200324T1/hr unknown
-
2020
- 2020-03-19 CY CY20201100258T patent/CY1122879T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE048755T2 (hu) | 2020-08-28 |
| SMT202000164T1 (it) | 2020-05-08 |
| ES2781756T3 (es) | 2020-09-07 |
| DK2976074T3 (da) | 2020-03-30 |
| CY1122879T1 (el) | 2021-05-05 |
| WO2014146699A1 (en) | 2014-09-25 |
| HRP20200324T1 (hr) | 2020-06-12 |
| US9662320B2 (en) | 2017-05-30 |
| RS60295B1 (sr) | 2020-07-31 |
| US20160067235A1 (en) | 2016-03-10 |
| PT2976074T (pt) | 2020-03-11 |
| EP2976074B1 (en) | 2020-01-01 |
| LT2976074T (lt) | 2020-03-25 |
| EP2976074A1 (en) | 2016-01-27 |
| SI2976074T1 (sl) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2976074T1 (sl) | Antagonisti kanabionidnega receptorja cb1 za uporabo pri tretiranju bolezni v povezavi z nevronskimi dendritičnimi anomalijami | |
| HUE054783T2 (hu) | Pridopidin Huntington-kór kezelésében | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| IL244748A0 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| SG11201509012QA (en) | Sobetirome in the treatment of myelination diseases | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| HUE068364T2 (hu) | Faktor 1 fehérje betegségek kézélésében vagy megelõzésében váló alkalmazásra | |
| HRP20190356T1 (hr) | Mimetici kalcitonina za liječenje bolesti i poremećaja | |
| IL240931A0 (en) | History 3 - Phenylpropylamine is converted to the treatment of eye diseases and disorders | |
| EP2967062A4 (en) | DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION | |
| EP2974730A4 (en) | MEDICINAL PRODUCTS FOR RESPIRATORY DISEASES | |
| HRP20181554T4 (hr) | Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja | |
| ZA201507718B (en) | The local treatment of inflammatory ophthalmic diseases | |
| HUE045148T2 (hu) | Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére | |
| FR3004424B1 (fr) | Marchepied amovible d'aeronef, et aeronef | |
| EP3058005C0 (en) | IN SITU ALKYLPHENOL ALDEHYDE RESINS | |
| IL246148A0 (en) | Treating brain disorders and biomarkers related thereto | |
| EP2949329A4 (en) | THERAPEUTIC AGAINST DEMYELINISING DISEASE | |
| HUE047174T2 (hu) | Imepitoin epilepsziás rendellenességek kezelésére történõ alkalmazásra macskafélékben | |
| GB201320506D0 (en) | Cyclic amino compounds for the use in the treatment of cardiac disorders | |
| UA25914S (uk) | Шпилька для з'єднання деталей транспортного засобу | |
| UA28653S (uk) | Шворінь поворотного з'єднання частин транспортного засобу | |
| UA26553S (uk) | Шворінь поворотного з'єднання частин транспортного засобу | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
| UA27047S (uk) | Редуктор до форматора-вулканізатора 75'' та 88'' |